Citizens Upgrades Quince Therapeutics to Market Outperform, Announces $77 Price Target

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben upgrades Quince Therapeutics (NASDAQ:QNCX) from Market Perform to Market Outperform and announces $77 price target.